Q-omics provides the consensus-scored METTL15P1 profile across patient tissues and cancer cell-line models. METTL15P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, METTL15P1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, METTL15P1 RNA expression shows 19,869 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where METTL15P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL15P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL15P1 survival associations across molecular data types. METTL15P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL15P1 RNA expression–survival associations across cancer types. High METTL15P1 expression shows unfavorable associations in LGG and PAAD, but favorable associations in KIRC, KIRP, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for METTL15P1 RNA expression.
This table summarizes METTL15P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for METTL15P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL15P1 shows lower tumor expression in THCA, COAD and UCEC and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher METTL15P1 RNA expression in normal versus tumor tissue (log2 FC = −0.653, t-test p < 0.001).
This table shows molecular features associated with METTL15P1 in patient tissues and cancer cell lines. In patient samples, METTL15P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
